Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: Efficacy and toxicity data from a retrospective study

Journal of Chemotherapy

Volumn 21, Issue 6, 2009, Pages 687-692

  Curigliano, Giuseppe ^a   Spitaleri, G ^a   Magni, E ^a   Lorizzo, K ^a   De Cobelli, O ^a   Locatelli, M ^a   Fumagalli, L ^a   Adamoli, L ^a   Cossu Rocca, M ^a   Verri, E ^a   De Pas, T ^a   Jereczek Fossa, E ^a   Martinelli, G ^b   Goldhksch, A ^a   Nole F ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Bleomycin; Cisplatin; Etoposide; Germ cells testicular cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CHILD; CONTINUOUS INFUSION; DRUG SAFETY; HUMAN; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OTOTOXICITY; OUTCOME ASSESSMENT; PARESTHESIA; RETROSPECTIVE STUDY; SCHOOL CHILD; SEMINOMA; VOMITING; CANCER STAGING; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; TESTIS TUMOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; RETROSPECTIVE STUDIES; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 77649293465     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.6.687     Document Type: Article

References (29)

1. Einhorn EH: Testicular cancer: An oncological success story. Clin Cancer Res, 1997; 3: 2630-2632,.
2. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-40.
3. Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S et al. A. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 1986; 4: 400-7.
4. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R, Omura G et al. Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: an SECSG protocol. J Clin Oncol 1989; 7: 387-91.
5. Loehrer PJ, Johnson D, Elson P, Einhorn LH, Trump D. The importance of bleomycin in favorable prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13: 470-6.
6. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw 2006; 4 (10):1059-70.
7. van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24 (3):467-75.
8. Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18(2):241-8.
9. Nuver J, Smit AJ, Wolffenbuttel BH, Sluiter WJ, Hoekstra HJ, Sleijfer DT, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23(16):3718-25.
10. Dahl AA, Bremnes R, Dahl O, Klepp O, Wist E, Fosså SD. Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol 2007;52(5):1438-47.
11. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25(6):708-14.
12. Kawai K, Akaza H. Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer. Expert Opin Drug Safety 2003; 2(6):587-96.
13. van Bameveld PW, Sleijfer DT, van der Mark TW, Mulder NH, Donker AJ, Meijer S, et al Influence of platinum-induced renal toxicity on bleomycin-induced pulmonary toxicity in patients with disseminated testicular carcinoma. Oncology 1984; 41(1):4-7.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
15. Simon R. Confidence interval for reporting results of clinical trials. Ann Intern Med 1986; 105(3): 429-435.
16. International Germ Cell Cancer Collaborative Group (IGCCCG). The International Germ Cell Consensus Gasification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 1997; 15:594-603.
17. Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A, Golbey RB, et al. A randomized trial of etoposide +cisplatin versus vinblastine + bleomycin + cisplatin + cyclophoshamide + dactinomycin in patients with god prognosis germ cell tumors. J Clin Oncol 1988; 6(8):1231-8.
18. Levi JA, Raghavan D, Harvey V, Thompson D, Sandeman T, Gill G, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol 1993;11(7):1300-5.
19. Stoter G, Kaye S, Sleyfer D, et al: Preliminary results of BEP (bleomycin, etoposide, cisplatin) versus EP in low volume metastatic (LVM) testicular non-seminomas. An EORTC study. Proc Am Soc Clin Oncol 1987;6:110, (abstr).
20. Gerson R, Tellez Bemal E, Lazaro Leon M, Sanchez Forgach E, Garcia Irigoyen C, Gutierrez Godinez F, et al. Low toxicity with continuous infusion of high-dose bleomycin in poor prognostic testicular cancer. Am J Clin Oncol 1993;16(4):323-6.
21. Remick SC, Reddy M, Herman D, Grace C, Harper G, Willis K, et al. Continuous infusion bleomycin in AIDS-related Kaposi's sarcoma J Clin Oncol 1994; 1130-1136.
22. de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular non seminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15(5):1837-43.
23. Manavis J, Ambatzoglou J, Sismanidou K, Koukourakis MI. Computed tomography scan evaluation of late toxicity following hypofractionated/ accelerated radiotherapy with cytoprotection in breast cancer treated with conservative surgery. Am J Clin Oncol 2006; 29 (5): 478-83.
24. Kondagunta GV, Bacik J, Bajorin D, Dobrzynski D, Sheinfeld J, Motzer RJ et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005;23(36):9290-4.
25. Perry DJ, Weiss RB, Taylor HG. Enhanced bleomycin toxicity during acute renal failure. Cancer Treat Rep 1982; 66:592-93.
26. Bennett WM, Pastore L, Houghton DC. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat Rep 1980;64:921-24.
27. Fosså SD, de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM et al. Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol 2003;21: 1107-18.
28. Waid-Jones MI, Coursin DB. Perioperative considerations for patients treated with bleomycin. Chest 1991;99: 993-9.
29. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F et al. European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 2008; 53:497-513.